AgingResearch.NewsJoin free

ACTIVEN

CompanySwitzerlandFounded 2006

ACTIVEN develops one asset, in human trials (XEPTM-716 Miniprotein in skin aging). Mostly protein or enzyme acting on TGFB1; based in Switzerland, founded in 2006.

1
Asset
Furthest stage
Human trials
0
Trials
1
Signal

Pipeline

1

  • XEPTM-716 Miniprotein

    Topical transforming growth factor-beta mimetic miniprotein that modulates epidermal morphometric features and cellular senescence.

    Human trials, Protein or enzyme, TGFB1, skin aging

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms2
  • Signals1
  • Similar companies6

Papers

Intelligence